Drugs / CCI15106
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03235726 | Jul 2017 → Jun 2018 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT03243760 | Feb → Jul 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CCI15106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03243760 ↗ |
| Route | Inhaled | “CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device” NCT03243760 ↗ |